Alto Neuroscience (ANRO) announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent protects an aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO: